BenevolentAI
5 followers
BenevolentAI combines advanced AI and machine learning with cutting edge science to decipher complex disease biology, generate novel insights and discover more effective medicines. Our unique computational R&D platform spans every step of the drug discovery process, powering an in-house pipeline of... Read more
Org chart
François Nader
Acting CEO & Chairman
François Nader
Collapse
Ivan Griffin
Co-Founder & COO
Anne Phelan
Chief Scientific Officer
Will Scrimshaw
General Counsel
Tom Holgate
SVP, Finance
Daniel Neil
SVP, Artificial Intelligence
Constantinos Neophytou
SVP, Engineering
Matthew Fujisawa
SVP, Strategy & Corporate Development
Nikki Robas
VP, Drug Discovery
Peter Cox
VP, Drug Discovery
Ed Savory
VP, Drug Discovery
Peter Richardson
VP, Pharmacology
Catherine Tucker
VP, Business Development
Rajin Kang
VP, Communications
Adepeju Oshisanya
VP, Clinical Programmes
Jane McGuffog
VP, Drug Discovery
Rachel Shaw
VP, Portfolio Management
Atima Bhatnagar
VP, Ops & Quality
James Dunbar
VP of Discovery Technology
Olly Oechsle
VP, Product Engineering
Eve Berry
VP of Finance Operations
Amy Gibson
VP of Legal
Nicola Richmond
VP, AI
Fleur Wood
VP, Investor Relations
Neal Lewis
VP of Platform Architecture
Teams
View all
